Meeting
2019 ASCO Annual Meeting
Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).
Authors
Priyanka Sharma
University of Kansas Medical Center, Kansas City, KS
Priyanka Sharma , Bruce F. Kimler , Anne O'Dea , Lauren Elizabeth Nye , Yen Y. Wang , Rachel Yoder , Lindsey Hastings Prochaska , Jamie L. Wagner , Amanda Leigh Amin , Kelsey Larson , Christa Balanoff , Manana Elia , Gregory James Crane , Sheshadri Madhusudhana , Marc Steven Hoffmann , Maureen Sheehan , Robert R. Rodriguez , Roy A. Jensen , Andrew K. Godwin , Qamar J. Khan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT02413320
Citation
J Clin Oncol 37, 2019 (suppl; abstr 516)
DOI
10.1200/JCO.2019.37.15_suppl.516
Abstract #
516
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
First Author: Laura Spring
Poster
2013 ASCO Annual Meeting
An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer.
First Author: Tiffany P. Avery
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant docetaxel + carboplatin versus epirubicin+cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label, phase II trial.
First Author: Liulu Zhang